Since Gavi was established in 2000 with a mission to save lives, reduce poverty and protect the world against the threat of epidemics and pandemics, it has helped vaccinate more than 1.1 billion children in 78 countries through the end of 2023 – and averted more than 18.8 million future deaths.
The progress seen in 2023 is a testament to the power of the Vaccine Alliance – from our core partners to the dedicated, passionate people in countries and communities upon whose hard work and expertise we rely every day to protect the next generation. The Alliance maintains a relentless focus on reaching the 11 million ‘zero-dose’ children who did not receive a single shot of basic vaccines in 2023.
As the core of Gavi’s work, life-saving immunisation represents a beacon of hope in these uncertain times: the foundation for the healthy future every child deserves, and on which our interconnected world depends.
Highlighting key data, partnerships and milestones, the 2023 Annual Progress Report offers insights into our progress last year, while facing the challenges ahead.
Highlighting key data, partnerships and milestones, the 2023 Annual Progress Report offers insights into our progress last year, while facing the challenges ahead.
Download reportHighlighting key data, partnerships and milestones, the 2023 Annual Progress Report offers insights into our progress last year, while facing the challenges ahead.
Download reportThe Vaccine Alliance’s mission is: to save lives and protect people’s health by increasing equitable and sustainable use of vaccines. Six “mission indicators” reflect our overall progress against our aspirations for the 2021–2025 period.
This mission is also supported by the following four strategic goals, each with its own set of strategy indicators.
With the exception of pentavalent vaccine, in aggregate all Gavi‑supported vaccines had higher coverage in 2023 than before the pandemic in 2019.
56 %
The 57 Gavi-supported countries increased breadth of protection with vaccines in the Gavi portfolio to 56%, up 3 percentage points from 2022.
In Gavi 5.0/5.1, health system strengthening (HSS) support prioritises equity in immunisation delivery, to reduce the number of zero-dose and under-immunised children.
80 %
In 2023, Gavi-supported countries maintained DTP3 coverage at 80% (compared to the 84% global average).
The year 2023 confirmed the robustness of the Vaccine Alliance’s co-financing approach and the steady financial commitment of countries, despite many countries facing increasing fragility.
US$ 1.7bn by end 2023
In the face of fiscal challenges, climate change, conflict and instability, most Gavi-supported countries maintained or increased domestic resources for co-financing of Gavi-supported vaccines in 2023, bringing to US$ 1.7 billion their total contribution since the introduction of the co-financing policy in 2008.
Gavi’s market shaping efforts make life-saving vaccines and other immunisation products more accessible and affordable for lower-income countries.
19
Through Gavi’s market shaping efforts, the number of manufacturers supplying prequalified Gavi-supported vaccines remained at 19 in 2023 (with more than half based in low- and middle-income countries) – compared with 5 in 2001.